Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07145177 · ClinicalTrials.gov registry record · Phase 1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

A Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT07145177 is a Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07145177, a Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.

Conditions Studied

Prostate Cancer Metastatic Prostate Cancer

Interventions

  • DRUG 177Lu-PSMA-617
  • PROCEDURE Tumor Biopsy
  • PROCEDURE Ablation
  • PROCEDURE Trans-arterial chemoembolization (TACE)
  • PROCEDURE Positron Emission Tomography (PET)/Computerized tomography (CT)

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-03-16
Est. Completion 2030-10-31
Phase Phase 1

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07145177

The ClinicalTrials.gov registry entry for NCT07145177 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which 177Lu-PSMA-617 is the first listed.

NCT07145177 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07145177 about?

NCT07145177 is a clinical study titled "177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer". This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases...

What is the current status of trial NCT07145177?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03-16. Estimated completion is 2030-10-31.

What conditions does trial NCT07145177 study?

This clinical trial studies the following conditions: Prostate Cancer, Metastatic Prostate Cancer.

What interventions are being tested in trial NCT07145177?

The interventions under investigation include: 177Lu-PSMA-617 (DRUG), Tumor Biopsy (PROCEDURE), Ablation (PROCEDURE), Trans-arterial chemoembolization (TACE) (PROCEDURE), Positron Emission Tomography (PET)/Computerized tomography (CT) (PROCEDURE).

Who is sponsoring clinical trial NCT07145177?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07145177 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Metastatic Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.